Clinical Trials Sponsored by Allergan Foundation

Total 20066 results

Allergan

Completed

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

Subcutaneous Fat

Germany
Allergan

Completed

Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light Exposure

Blue Light Damage

United States
Allergan

Completed

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

Migraine Disorders

United States
Allergan

Terminated

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Allergan

Completed

OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Depressive Disorder, Major

United States
Allergan

Completed

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

Dry Eye Syndromes

United States, Australia
Allergan

Completed

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder (COMFORT)

Overactive Bladder

United States
Allergan

Completed

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Allergan

Completed

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Allergan

Withdrawn

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Migraine Disorders
Allergan

Completed

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

Migraine Disorders

United States, Australia, Korea, Republic of
Allergan

Completed

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Migraine
Allergan

Completed

Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

Urinary Bladder, Overactive | Urinary Incontinence

Korea, Republic of
Allergan

Completed

Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants (RANBI)

Breast Implantation

France, Spain, Germany, Israel, United Kingdom
Allergan

Completed

Retrospective Study of Reoperation After Primary Augmentation With NATRELLE® INSPIRA® Breast Implants (RANBI-I)

Breast Implantation

Canada
Allergan

Completed

A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

Overactive Bladder | Urinary Incontinence

Korea, Republic of
Allergan

Completed

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

Multiple Sclerosis | Urinary Bladder Diseases

United States
Allergan

Completed

An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder (GRACE)

Urinary Bladder, Overactive | Urinary Incontinence

United Kingdom, Germany, Spain, Sweden
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache

Migraine Disorders | Headache

United States
Allergan

Completed

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Conjunctivitis, Allergic

Japan
Allergan

Completed

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Macular Edema | Retinal Vein Occlusion

France
Allergan

Terminated

Safety and Efficacy of AGN201781 in Neuropathic Pain

Neuralgia

Germany, Australia
Allergan

Completed

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Presbyopia

United States
Allergan

Withdrawn

Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs (STRETCh)

Muscle Spasticity

United States
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
Allergan

Completed

Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)

Chronic Migraine

United States
Allergan

Terminated

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Serbia, Turkey, Greece, Egypt, Lebanon, India
Allergan

Completed

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Chronic Migraine, Headaches

United States
Allergan

Terminated

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

Age-Related Macular Degeneration | Choroid Neovascularization

United States, Australia, Philippines
Allergan

Completed

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

Dry Eye Syndrome

United States
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Chronic Migraine Epidemiology and Outcomes Study

Migraine Disorders
Allergan

Completed

Tear Collection in Adult Volunteers

Healthy Volunteers

Australia
Allergan

Completed

MDs on Botox Utility (MOBILITY)

Strabismus | Torticollis | Muscle Spasticity | Blepharospasm

Canada
Allergan

Completed

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Mexico, Colombia
Allergan

Withdrawn

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Stroke | Muscle Spasticity
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Diabetic Macular Edema

United Kingdom, Taiwan, Colombia, Korea, Republic of, Singapore, Brazil, New Zealand, Poland, Hungary, Italy, India, France, United States, Canada
Allergan

Completed

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension (APOTUS)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Cervical Dystonia | Blepharospasm

Norway, United Kingdom
Allergan

Completed

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Germany, Netherlands
Allergan

Completed

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

Macular Edema | Retinal Vein Occlusion

South Africa, Canada, United States, Australia, Israel
Allergan

Completed

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Conjunctivitis, Allergic

Korea, Republic of
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States, Germany
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease

Dry Eye Syndromes

Germany
Allergan

Completed

AGN-229666 for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Allergan

Completed

Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

Dry Eye Syndromes

United Kingdom
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany

3

Subscribe